NCT02590588View on ClinicalTrials.gov

Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

March 27, 2017

Study Completion Date

March 27, 2017

Conditions
Amyloidosis
Interventions
DRUG

Idelalisib

Idelalisib daily until unacceptable toxicity or disease progression.

Trial Locations (1)

02118

Boston Medical Center, Boston

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

John Mark Sloan

OTHER